Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merus N.V. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
MRUS
Nasdaq
2830
www.merus.nl
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merus N.V.
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
- Feb 5th, 2025 10:00 pm
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential
- Jan 17th, 2025 4:08 pm
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth
- Jan 15th, 2025 5:13 pm
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
- Jan 13th, 2025 1:04 am
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’
- Jan 7th, 2025 8:05 pm
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
- Dec 16th, 2024 9:01 pm
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
- Dec 10th, 2024 5:07 pm
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
- Dec 7th, 2024 6:30 am
Merus Scores Its First FDA Approval For Lung Cancer Drug
- Dec 5th, 2024 7:49 pm
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
- Dec 5th, 2024 4:35 pm
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
- Dec 4th, 2024 9:55 pm
Merus price target lowered to $109 from $111 at Guggenheim
- Dec 4th, 2024 11:45 am
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
- Dec 2nd, 2024 5:47 pm
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
- Dec 2nd, 2024 1:00 pm
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
- Dec 1st, 2024 4:05 pm
Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds
- Nov 23rd, 2024 3:47 pm
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
- Nov 15th, 2024 7:08 am
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?
- Nov 13th, 2024 3:48 pm
Merus to Present at Upcoming Investor Conferences
- Nov 6th, 2024 9:01 pm
Merus Receives FDA extension of PDUFA for zenocutuzumab
- Nov 5th, 2024 11:30 am
Scroll